Last news
Constellation Brands Closes Wine Transaction With The Wine Group to Focus on a Portfolio of Exclusively Higher-Growth, Higher-Margin Brands

Constellation Brands Closes Wine Transaction With The Wine Group to Focus on a Portfolio of Exclusively Higher-Growth, Higher-Margin Brands

Notified -...

GBI Launches Green Globes® Data Center Campus Certification Alongside Compass Datacenters for Sustainable Digital Infrastructure

GBI Launches Green Globes® Data Center Campus Certification Alongside Compass Datacenters for Sustainable Digital Infrastructure

Notified -...

Denodo University Challenge Now Open: Data and AI for Real-World Impact

Denodo University Challenge Now Open: Data and AI for Real-World Impact

Notified -...

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

Notified -...

Gatorade 5v5 Finals Bring Global Youth to Champions League Stage in Munich

Gatorade 5v5 Finals Bring Global Youth to Champions League Stage in Munich

Notified -...

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

Notified -...

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with T

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with T

Notified -...

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with T

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with T

Notified -...

1 ... 251 252 253 254 255 256 257 258 259 ... 1063
menu
menu